Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
Josef Thaler(Thrombolysis in Myocardial Infarction Study Group), Mohamed-Ayman Zawadi, Jos Janssens(Hospital Clínico San Carlos), Hassan RezaieKalantari, Robert Steinacher, Marc Ychou(Université de Montpellier), Ghislain Houbiers, Joseph Kerger(Institut Jules Bordet), Ewald Woell, Marc Peeters(University of Antwerp), Johannes Gaenzer, A. Lenauer, Guido Deboever, Thierry Delaunoit, G. Ghillebert, Alois Lang(Landeskrankenhaus Feldkirch), Ayman Zawadi, Richard Greil(Paracelsus Medical University), Erik Vanderstraeten, Philippe Vergauwe, Geert D’Haens(Amsterdam University Medical Centers), Alain Hendlisz(London Cancer), Wolfgang Eisterer(Klinikum Klagenfurt), Lene Weber Vestermark, Marc Polus, R. Függer(Johannes Kepler University of Linz), Michel Ferrante, Gauthier Demolin, August Zabernigg, Eric Van Cutsem(Universitair Ziekenhuis Leuven), Mette Yilmaz, Daniel Van Daele, Hellmut Samonigg(Graz University Hospital), Dirk Schrijvers(ZNA Middelheim Hospital), Jean–Luc Van Laethem, Jim Larsen, Franz X. Schmid(University of Bayreuth), Frédéric Forget, Johannes Andel(Engineering Software Steyr (Austria)), Günther Steger(Barwon Health), D. Geißler(Klinikum Klagenfurt), Svend Erik Nielsen, Manfred Prager, Yves Humblet(Deventer Ziekenhuis), F Hofbauer, Jean Charles. Goeminne, Jan B. Vermorken(University of Antwerp)
Cited by 4
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k